company coverage
Innate Pharma research (EURONEXT-PARIS:IPH)
Coverage of Innate Pharma collects dated research on business quality, return drivers, balance-sheet resilience, valuation scenarios, and what would change the thesis for EURONEXT-PARIS:IPH.
1 edition linked in this hub.
Coverage
- 11 Aug 2026Sobi's $75m cheque changes Innate Pharma's runway before Phase IIIInnate Pharma (EURONEXT-PARIS:IPH) gained 21.49% after licensing lacutamab. The cash matters; the $580m headline still depends on Phase III.